UBS upgrades CVS to buy rating, sees further recovery ahead

UBS upgraded CVS Health to a Buy rating from Neutral, raising its price target by 18% to $79, implying 15% additional upside. The upgrade is predicated on expectations for sustained double-digit long-term EPS growth, primarily from a recovering healthcare benefits segment where recent Medicare Advantage assumptions have proven accurate. Analysts project CVS will achieve $7.20 EPS by FY2026 and 14% compound annual growth through 2028, noting the stock trades at an attractive 9x 2026 estimated earnings, below its 10-year average.

Analysis

UBS has upgraded CVS Health to a Buy rating from Neutral, increasing its price target by 18% to $79, which suggests a 15% potential upside from its recent closing price. This upgrade follows a significant 53% year-to-date surge in the stock. The core of the bullish thesis rests on the successful turnaround of the company's healthcare benefits (HCB) segment, evidenced by two consecutive strong quarters and management's accurate forecasting of Medicare Advantage (MA) utilization trends. UBS highlights a key catalyst: the repricing of approximately 50% of its multi-year group MA contracts this year, which are currently operating at a negative mid-to-high single-digit margin. The bank's analyst, Kevin Caliendo, projects a more optimistic earnings trajectory than the market consensus, forecasting $7.20 EPS by fiscal year 2026 (versus a $7.15 consensus) and a 14% compound annual EPS growth rate through 2028, surpassing the Street's 12% estimate. Despite the stock's strong performance, the valuation is viewed as attractive, with shares trading at 9 times estimated 2026 earnings, a discount to the 10-year average of 10 times.

Key Decisions for Investors

• Investors could consider the stock based on the potential for sustained double-digit EPS growth, driven by the HCB segment recovery and a valuation that remains below its historical average.
• It is critical to monitor upcoming earnings reports for continued margin improvement in the healthcare benefits segment, particularly tracking the financial impact of the Medicare Advantage contract repricing.
• Given the stock's 53% year-to-date appreciation, investors should weigh the forecasted 15% upside against the risk of execution missteps or a slowdown in the HCB segment's recovery momentum.